Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [142]
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Research works printed but not linked: 3
- D. Pardoll, Nature411, 1010 (2001).
- Y. Naito et al., Cancer Res.58, 3491 (1998).
- We thank A. Rodi and M. Pelegrin for expert technical assistance; I. Gresser for helpful comments and critical review of the manuscript; and D. Frucht C. Anderson and T. Pokrovska for critically reading the manuscript. Supported by the Association pour la Recherche sur le Cancer (ARC) through the Alliance pour la Recherche sur le Cancer network (ARECA) INSERM Action Concertée Incitative ACI IMPBio Université Paris-Descartes Paris 5 and the Austrian Federal Ministry of Education Science and Culture (GBN-AU project Bioinformatics Integration Network).
Cited by
Items 601–700 of 1,043
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R., Lesh, R. W., Ali, U., Kubiak, M., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 196
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
Nagalla, S., Chou, J. W., Willingham, M. C., Ruiz, J., Vaughn, J. P., Dubey, P., Lash, T. L., Hamilton-Dutoit, S. J., Bergh, J., Sotiriou, C., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r34 · Cited by 196
Xiong, Y., Wang, K., Zhou, H., Peng, L., You, W., & Fu, Z. (2018) · Cancer Medicine · doi:10.1002/cam4.1745 · Cited by 195
Chen, T., Li, Q., Wu, J., Wu, Y., Peng, W., Li, H., Wang, J., Tang, X., Peng, Y., & Fu, X. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2233-x · Cited by 195
Shen, Z., Zhou, S., Wang, Y., Li, R.-L., Zhong, C., Liang, C., & Sun, Y. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0816-9 · Cited by 195
Geis, A. L., Fan, H., Wu, X., Wu, S., Huso, D. L., Wolfe, J. L., Sears, C. L., Pardoll, D. M., & Housseau, F. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0447 · Cited by 195
Immunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Martinet, L., Le Guellec, S., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J.-P. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 193
Sadot, E., Koerkamp, B. G., Leal, J. N., Shia, J., Gonen, M., Allen, P. J., DeMatteo, R. P., Kingham, T. P., Kemeny, N., Blumgart, L. H., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001427 · Cited by 193
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 193
Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma
Fang, J., Li, X., Ma, D., Liu, X., Chen, Y., Wang, Y., Lui, V. W. Y., Xia, J., Cheng, B., & Wang, Z. (2017) · BMC Cancer · doi:10.1186/s12885-017-3317-2 · Cited by 193
Natural immunity to cancer in humans
Bindea, G., Mlecnik, B., Fridman, W.-H., Pagès, F., & Galon, J. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.006 · Cited by 192
Self-citationMahajan, U. M., Langhoff, E., Goni, E., Costello, E., Greenhalf, W., Halloran, C., Ormanns, S., Kruger, S., Boeck, S., Ribback, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.009 · Cited by 192
Zeng, D.-Q., Yu, Y.-F., Ou, Q.-Y., Li, X.-Y., Zhong, R.-Z., Xie, C.-M., & Hu, Q.-G. (2016) · Oncotarget · doi:10.18632/oncotarget.7282 · Cited by 192
Wennerberg, E., Kremer, V., Childs, R., & Lundqvist, A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1629-5 · Cited by 192
“These chemokines as well as CXCL11 (interferon-inducible T cell alpha chemoattractant, I-TAC) attract cells expressing the CXCR3 chemokine receptor [29], and secretion of CXCR3 ligands is associated with recruitment and infiltration of CXCR3-positive CTLs in several malignancies including renal cell carcinoma and mela…”
BackgroundOccurrence and significance of tumor‐associated neutrophils in patients with colorectal cancer
Galdiero, M. R., Bianchi, P., Grizzi, F., Di Caro, G., Basso, G., Ponzetta, A., Bonavita, E., Barbagallo, M., Tartari, S., Polentarutti, N., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30076 · Cited by 192
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim, T. K., Herbst, R. S., & Chen, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.001 · Cited by 192
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle, P. A., Kufer, P., & Bargou, R. C. (2009) · PubMed · Cited by 192
Tosolini, M., Pont, F., Poupot, M., Vergez, F., Nicolau-Travers, M.-L., Vermijlen, D., Sarry, J. E., Dieli, F., & Fournié, J.-J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284723 · Cited by 191
Self-citationEpigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 191
Ling, K. L., Pratap, S., Bates, G. J., Singh, B., Mortensen, N. J. M., George, B. D., Warren, B. F., Piris, J., Roncador, G., Fox, S. B., et al. (2007) · PubMed · Cited by 191
Racial and ethnic disparities in colorectal cancer incidence and mortality
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2021.02.007 · Cited by 190
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Kargl, J., Zhu, X., Zhang, H., Yang, G. H. Y., Friesen, T. J., Shipley, M., Maeda, D. Y., Zebala, J. A., McKay-Fleisch, J., Meredith, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130850 · Cited by 190
In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide
Remark, R., Merghoub, T., Grabe, N., Litjens, G., Damotte, D., Wolchok, J. D., Merad, M., & Gnjatic, S. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf6925 · Cited by 190
Pasetto, A., Gros, A., Robbins, P. F., Deniger, D. C., Prickett, T. D., Matus-Nicodemos, R., Douek, D. C., Howie, B., Robins, H., Parkhurst, M. R., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0001 · Cited by 190
Bai, Z., Zhou, Y., Ye, Z., Xiong, J., Lan, H., & Wang, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.808964 · Cited by 189
T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune Responses
Zhu, Y., Ju, S., Chen, E., Dai, S., Li, C., Morel, P., Liu, L., Zhang, X., & Lu, B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000749 · Cited by 189
Cancer Genomics: Technology, Discovery, and Translation
Tran, B., Dancey, J. E., Kamel-Reid, S., McPherson, J. D., Bedard, P. L., Brown, A. M. K., Zhang, T., Shaw, P., Onetto, N., Stein, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2316 · Cited by 188
Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy
Shafabakhsh, R., Pourhanifeh, M. H., Mirzaei, H. R., Sahebkar, A., Asemi, Z., & Mirzaei, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104353 · Cited by 188
Song, H., Srivastava, A., Lee, J., Kim, Y. S., Kim, K., Ki Kang, W., Kim, M., Kim, S., Park, C. K., & Kim, S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.002 · Cited by 188
Role of Cancer Microenvironment in Metastasis: Focus on Colon Cancer
Gout, S., & Huot, J. (2008) · Cancer Microenvironment · doi:10.1007/s12307-008-0007-2 · Cited by 187
Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
Gordon-Alonso, M., Hirsch, T., Wildmann, C., & van der Bruggen, P. (2017) · Nature Communications · doi:10.1038/s41467-017-00925-6 · Cited by 186
Schetter, A. J., Nguyen, G. H., Bowman, E. D., Mathé, E. A., Yuen, S. T., Hawkes, J. E., Croce, C. M., Leung, S. Y., & Harris, C. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0627 · Cited by 185
Hendrickx, W., Simeone, I., Anjum, S., Mokrab, Y., Bertucci, F., Finetti, P., Curigliano, G., Seliger, B., Cerulo, L., Tomei, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1253654 · Cited by 185
Wnt signaling and colon carcinogenesis: Beyond APC
Najdi, R., Holcombe, R., & Waterman, M. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.78111 · Cited by 184
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Califano, J. A., Khan, Z., Noonan, K. A., Rudraraju, L., Zhang, Z., Wang, H., Goodman, S., Gourin, C. G., Ha, P. K., Fakhry, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1716 · Cited by 184
Targeting microRNAs as key modulators of tumor immune response
Paladini, L., Fabris, L., Bottai, G., Raschioni, C., Calin, G. A., & Santarpia, L. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0375-2 · Cited by 184
Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity
Dean, I., Lee, C. Y. C., Tuong, Z. K., Li, Z., Tibbitt, C. A., Willis, C., Gaspal, F., Kennedy, B. C., Matei-Rascu, V., Fiancette, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44789-z · Cited by 183
Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches
Franke, A. J., Skelton, W. P., Starr, J. S., Parekh, H., Lee, J. J., Overman, M. J., Allegra, C., & George, T. J. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz093 · Cited by 183
“Some studies have shown peritumoral immune infiltration to be a more useful and predictive surrogate marker of disease progression than the standardized American Joint Committee on Cancer TNM staging system (15,23).”
BackgroundDe Palma, M., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 183
Erratum: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.24 · Cited by 183
Cancer Immunoediting in the Era of Immuno-oncology
Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 183
Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
Economopoulou, P., de Bree, R., Kotsantis, I., & Psyrri, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00827 · Cited by 181
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 181
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival
Yang, I., Tihan, T., Han, S. J., Wrensch, M. R., Wiencke, J., Sughrue, M. E., & Parsa, A. T. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.03.031 · Cited by 181
Clark, C. E., Beatty, G. L., & Vonderheide, R. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.037 · Cited by 181
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Tumor infiltrating B-cells are increased in prostate cancer tissue
Woo, J. R., Liss, M. A., Muldong, M. T., Palazzi, K., Strasner, A., Ammirante, M., Varki, N., Shabaik, A., Howell, S., Kane, C. J., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-30 · Cited by 180
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., & Noman, M. Z. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00021 · Cited by 180
The function and dysfunction of memory CD 8+ T cells in tumor immunity
Reading, J. L., Gálvez‐Cancino, F., Swanton, C., Lladser, A., Peggs, K. S., & Quezada, S. A. (2018) · Immunological Reviews · doi:10.1111/imr.12657 · Cited by 180
Suzuki, H., Chikazawa, N., Tasaka, T., Wada, J., Yamasaki, A., Kitaura, Y., Sozaki, M., Tanaka, M., Onishi, H., Morisaki, T., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0781-9 · Cited by 180
Irwin, K. E., Greer, J. A., Khatib, J., Temel, J. S., & Pirl, W. F. (2013) · Chronic Respiratory Disease · doi:10.1177/1479972312471549 · Cited by 180
Demotte, N., Wieërs, G., Van Der Smissen, P., Moser, M., Schmidt, C., Thielemans, K., Squifflet, J.-L., Weynand, B., Carrasco, J., Lurquin, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0761 · Cited by 179
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
Self-citationMultiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
Halse, H. M., Colebatch, A. J., Petrone, P., Henderson, M. A., Mills, J. K., Snow, H. A., Westwood, J. A., Sandhu, S. K., Raleigh, J., Behren, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28944-3 · Cited by 179
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Haas, C., Krinner, E., Brischwein, K., Hoffmann, P., Lutterbüse, R., Schlereth, B., Kufer, P., & Baeuerle, P. A. (2009) · Immunobiology · doi:10.1016/j.imbio.2008.11.014 · Cited by 178
High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
Wu, X., He, X., Chen, Y., Yuan, R., Zeng, Y., Lian, L., Zou, Y., Lan, N., Wu, X., & Lan, P. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23056 · Cited by 178
Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?
Özdemir, B. C., & Dotto, G.-P. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.02.002 · Cited by 178
Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma
Faraj, S. F., Munari, E., Guner, G., Taube, J., Anders, R., Hicks, J., Meeker, A., Schoenberg, M., Bivalacqua, T., Drake, C., et al. (2015) · Urology · doi:10.1016/j.urology.2014.10.020 · Cited by 178
Shi, S.-J., Wang, L.-J., Wang, G.-D., Guo, Z.-Y., Wei, M., Meng, Y.-L., Yang, A.-G., & Wen, W.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076012 · Cited by 178
Tougeron, D., Fauquembergue, É., Rouquette, A., Pessot, F. L., Sesboüé, R., Laurent, M., Berthet, P., Mauillon, J., Fiore, F. D., Sabourin, J., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.80 · Cited by 178
The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact
Fridman, W. H., Dieu‐Nosjean, M., Pagès, F., Cremer, I., Damotte, D., Sautès‐Fridman, C., & Galon, J. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0124-9 · Cited by 178
Self-citationGiraldo, N. A., Nguyen, P., Engle, E. L., Kaunitz, G. J., Cottrell, T. R., Berry, S., Green, B., Soni, A., Cuda, J. D., Stein, J. E., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0404-0 · Cited by 177
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille-Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 177
Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer
Lee, J. H. (2012) · Archives of Surgery · doi:10.1001/archsurg.2012.35 · Cited by 176
Prognostic Immune Markers in Non–Small Cell Lung Cancer
Suzuki, K., Kachala, S. S., Kadota, K., Shen, R., Mo, Q., Beer, D. G., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2805 · Cited by 176
Lymphangiogenesis guidance by paracrine and pericellular factors
Vaahtomeri, K., Karaman, S., Mäkinen, T., & Alitalo, K. (2017) · Genes & Development · doi:10.1101/gad.303776.117 · Cited by 176
Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
Nambiar, D. K., Aguilera, T., Cao, H., Kwok, S., Kong, C., Bloomstein, J., Wang, Z., Rangan, V. S., Jiang, D., von Eyben, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129025 · Cited by 176
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12
Uribe-Herranz, M., Bittinger, K., Rafail, S., Guedan, S., Pierini, S., Tanes, C., Ganetsky, A., Morgan, M. A., Gill, S., Tanyi, J. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94952 · Cited by 175
“Introduction Infiltration of primary tumors by Th1 and cytotoxic T cells provides one of the strongest prognostic factors for outcome at all stages of disease (1, 2).”
BackgroundImmunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
“Moreover, several immunological correlates of treatment, such as therapy-driven tumor infiltration by CD8þ cytotoxic T lymphocytes (CTLs) over CD4þCD25þFOXP3þ regulatory T (Treg) cells, or the activation of a type I interferon (IFN) response, have been associated with robust prognostic value in cohorts of patients aff…”
BackgroundMechanism of Action of Immunotherapy
Disis, M. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.004 · Cited by 175
FOXP3 and survival in urinary bladder cancer
Winerdal, M. E., Marits, P., Winerdal, M., Hasan, M., Rosenblatt, R., Tolf, A., Selling, K., Sherif, A., & Winqvist, O. (2011) · BJU International · doi:10.1111/j.1464-410x.2010.10020.x · Cited by 175
Roxburgh, C. S. D., & McMillan, D. C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.001 · Cited by 175
CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy
Rosenberg, J., & Huang, J. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.11.006 · Cited by 175
GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas
Roth, P., Junker, M., Tritschler, I., Mittelbronn, M., Dombrowski, Y., Breit, S. N., Tabatabai, G., Wick, W., Weller, M., & Wischhusen, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0705 · Cited by 175
Multiparametric immune profiling in HPV– oral squamous cell cancer
Feng, Z., Bethmann, D., Kappler, M., Ballesteros-Merino, C., Eckert, A., Bell, R. B., Cheng, A., Bui, T., Leidner, R., Urba, W. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93652 · Cited by 175
Martinet, L., Filleron, T., Guellec, S. L., Rochaix, P., Garrido, I., & Girard, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300872 · Cited by 175
Cancer immune contexture and immunotherapy
Becht, É., Giraldo, N. A., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.11.009 · Cited by 176
Self-citationKirilovsky, A., Marliot, F., El Sissy, C., Haicheur, N., Galon, J., & Pagès, F. (2016) · International Immunology · doi:10.1093/intimm/dxw021 · Cited by 157
Self-citationRecent advances and applications of CRISPR-Cas9 in cancer immunotherapy
Liu, Z., Shi, M., Ren, Y., Xu, H., Weng, S., Ning, W., Ge, X., Liu, L., Guo, C., Duo, M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01738-6 · Cited by 176
Inflammation and Colorectal Cancer
Long, A. G., Lundsmith, E. T., & Hamilton, K. E. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0373-6 · Cited by 174
Moeini, A., Sia, D., Zhang, Z., Camprecios, G., Stueck, A., Dong, H., Montal, R., Torrens, L., Martinez-Quetglas, I., Fiel, M. I., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.010 · Cited by 174
The Inflammatory Microenvironment in Colorectal Neoplasia
McLean, M. H., Murray, G. I., Stewart, K. N., Norrie, G., Mayer, C., Hold, G. L., Thomson, J., Fyfe, N., Hope, M., Mowat, N. A. G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015366 · Cited by 174
Role of T lymphocytes in tumor response to radiotherapy
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00095 · Cited by 174
Kamran, N., Kadiyala, P., Saxena, M., Candolfi, M., Li, Y., Moreno-Ayala, M. A., Raja, N., Shah, D., Lowenstein, P. R., & Castro, M. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.003 · Cited by 174
The immune contexture of primary and metastatic human tumours
Giraldo, N. A., Becht, É., Remark, R., Damotte, D., Sautès‐Fridman, C., & Fridman, W. H. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.001 · Cited by 175
Self-citationGene therapy: progress and predictions
Collins, M. K., & Thrasher, A. J. (2015) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2014.3003 · Cited by 176
Yang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
Lynch, K., Young, S. J., Meneveau, M. O., Wages, N. A., Engelhard, V. H., Slingluff, C. L., & Mauldin, I. S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002273 · Cited by 174
Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis
Yu, A. I., Zhao, L., Eaton, K. A., Ho, S., Chen, J., Poe, S., Becker, J., Gonzalez, A., McKinstry, D., Hasso, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.035 · Cited by 173
Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 173
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
Kather, J. N., Halama, N., & Jaeger, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.010 · Cited by 150
The impact of T‐cell immunity on ovarian cancer outcomes
Nelson, B. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00614.x · Cited by 172
“An excellent example is provided by a recent study of colorectal cancer, where expression analysis of multiple immunologically relevant genes revealed a strong correlation between Th1 immune responses and favorable prognosis (18).”
BackgroundT lymphocyte subsets in cancer immunity: Friends or foes
Chraa, D., Naim, A., Olive, D., & Badou, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-097r · Cited by 172
Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far?
Sagaert, X., Vanstapel, A., & Verbeek, S. (2018) · Pathobiology · doi:10.1159/000486721 · Cited by 172
Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer
Meraviglia, S., Lo Presti, E., Tosolini, M., La Mendola, C., Orlando, V., Todaro, M., Catalano, V., Stassi, G., Cicero, G., Vieni, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1347742 · Cited by 172
Self-citationNishiwada, S., Sho, M., Yasuda, S., Shimada, K., Yamato, I., Akahori, T., Kinoshita, S., Nagai, M., Konishi, N., & Nakajima, Y. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0144-7 · Cited by 172
He, S., Cheng, P., & Pu, K. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01009-1 · Cited by 172
Metadata
- Authors
- Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Pagès, F.
- Affiliations
- INSERM U 255, Paris, 75006 France; Université Paris-Descartes Paris 5, Faculté de Médecine, Paris, 75006 France; and Université Pierre et Marie Curie Paris 6, Institut des Cordeliers, Paris, 75006 France.
- Inserm (FR)
- ORCID
- Venue
- Science
- Published
- 2006-09-29
- Volume
- 313
- Issue
- 5795
- Pages
- 1960-1964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2142300779
- Cited by
- 6,516
- References
- 31
- Citations by year
- 2026: 237 · 2025: 278 · 2024: 329 · 2023: 444 · 2022: 451 · 2021: 574 · 2020: 524 · 2019: 433 · 2018: 447 · 2017: 405 · 2016: 394 · 2015: 380 · 2014: 268 · 2013: 282 · 2012: 237
- FWCI
- 70.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, tumor-infiltrating immune cells, adaptive immune response, prognostic factors, patient survival, tumor immune microenvironment, gene expression profiling, cancer immunotherapy
- MeSH terms
- Female, Humans, Immunohistochemistry, Immunologic Memory, Lymphatic Metastasis, Male, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Colorectal Neoplasms, Cohort Studies, Survival Analysis, Polymerase Chain Reaction, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD3 Complex, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Th1 Cells, Disease Progression, Disease-Free Survival, Lymphocyte Count, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.